Mandate

Investor Growth Capital new principle owner in Doxa

July 19, 2006

Through a special issue of shares, Investor Growth Capital will become the principle owner of the Uppsala-based medical technology company Doxa. Doxa develops new biomaterial for medical use. Since 2002, work has concentrated on rapidly growing field of orthopaedics. The infusion of capital will finance continued development of their biomaterial.

Vinge acted as advisor to Investor Growth Capital. Vinge representatives included Johan Winnerblad and Tom Zachrisson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026